Midwife:
Should be good, but is only indicated for refractory postpartum depression. Brexanolone is a neuroactive steroid modulator similar in structure to allopregnanolone. It is active at the steroid gamma-aminobutyric acid (GABA) receptor. The manufacturer reports that data from a lactation study in 12 women who received intravenous doses of 90 mg/kg/hour for 60 hours, that levels of brexanolone transferred to breastmilk was exceedingly low with an RID of 1-2% of maternal dose. In addition, because brexanolone has low oral bioavailability (<5%) in adults, infant exposure is expected to be low. Concentrations of brexanolone in breast milk were at low levels (<10 ng/mL) in >95% of women by 36 hours after the end of the infusion. Adverse events in breastfeeding infants are not expected.
Tom Hale Ph.D.
- The recommendations the InfantRisk Center provides are not meant to replace medical advice from your physician. The ultimate decision to breastfeed while taking medications should be based on an informed decision including available data, discussions between a mother, her physician, and the infants' pediatrician. The decision to take medications during pregnancy should be based available data and a discussion between a mother and her OB/GYN. To ask a question, Create an Account or Login.
Leave a comment: